CLN-978 Clinical Trials
3 recruitingDrug
Phase 13
Showing 1–3 of 3 trials
Recruiting
Phase 1
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
Sjogren's SyndromeSjogren DiseaseSjögren
Cullinan Therapeutics Inc.36 enrolled11 locationsNCT07041099
Recruiting
Phase 1
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
SLESLE (Systemic Lupus)
Cullinan Therapeutics Inc.24 enrolled15 locationsNCT06613360
Recruiting
Phase 1
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
Cullinan Therapeutics Inc.37 enrolled2 locationsNCT06994143